• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis.

作者信息

McCormack Lindsay, Ponce Joseph, Chatterjee Avik, Tan Jennifer K

机构信息

Boston Health Care for the Homeless Program, Boston, Massachusetts.

Massachusetts General Hospital, Department of Dermatology, Boston, Massachusetts.

出版信息

JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. eCollection 2021 Apr.

DOI:10.1016/j.jdcr.2020.12.031
PMID:33732840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7941000/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bb1/7941000/9eabc4adaf5b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bb1/7941000/9eabc4adaf5b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bb1/7941000/9eabc4adaf5b/gr1.jpg

相似文献

1
Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis.奥昔布宁治疗丁丙诺啡-纳洛酮引起的多汗症。
JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. eCollection 2021 Apr.
2
Suboxone (buprenorphine/naloxone) toxicity in pediatric patients: a case report.儿童患者中丁丙诺啡/纳洛酮复合制剂（舒泊西酮）中毒：一例报告
Pediatr Emerg Care. 2007 Sep;23(9):651-2. doi: 10.1097/PEC.0b013e31814a6aac.
3
Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.阿片类药物成瘾的丁丙诺啡注射者：格鲁吉亚共和国12周丁丙诺啡-纳洛酮或美沙酮治疗期间及之后的药物使用情况
J Subst Abuse Treat. 2015 Mar;50:32-7. doi: 10.1016/j.jsat.2014.10.003. Epub 2014 Oct 22.
4
A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.丁丙诺啡 - 纳洛酮复方片剂（舒倍生）治疗阿片类物质依赖的一项试点研究。
Drug Alcohol Rev. 2004 Sep;23(3):311-7. doi: 10.1080/09595230412331289473.
5
Group medication management for buprenorphine/naloxone in opioid-dependent veterans.针对阿片类药物依赖退伍军人的丁丙诺啡/纳洛酮集体药物管理
J Addict Med. 2014 Nov-Dec;8(6):415-20. doi: 10.1097/ADM.0000000000000071.
6
Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone® for chronic pain: a case report.一名长期使用舒泊西汀（Suboxone®）治疗慢性疼痛并接受克拉吉特窗闭合术患者的围手术期管理：病例报告
Can J Anaesth. 2014 Sep;61(9):826-31. doi: 10.1007/s12630-014-0193-y. Epub 2014 Jul 2.
7
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.将丁丙诺啡 - 纳洛酮脱毒疗法推广至社区治疗机构：美国国立药物滥用研究所临床试验网络的实地经验
Am J Addict. 2004;13 Suppl 1(Suppl 1):S42-66. doi: 10.1080/10550490490440807.
8
Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.在英国毒品战略框架下，通过医疗手段戒除阿片类药物依赖：美沙酮和丁丙诺啡-纳洛酮（苏立文）患者的比较。
J Subst Abuse Treat. 2013 Jan;44(1):97-102. doi: 10.1016/j.jsat.2012.04.003. Epub 2012 Jun 15.
9
Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification.阿片类拮抗剂、部分激动剂及激动剂/拮抗剂：门诊戒毒的作用
Pain Physician. 2008 Mar-Apr;11(2):225-35.
10
Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.州医疗补助人群中转用 Bunavail 后，丁丙诺啡/纳洛酮处方量下降。
Adv Ther. 2018 Apr;35(4):457-466. doi: 10.1007/s12325-018-0696-y. Epub 2018 Apr 6.

本文引用的文献

1
Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment.阿片类药物使用障碍和 COVID-19 大流行：呼吁维持监管放宽，并进一步扩大治疗机会。
Subst Abus. 2020;41(2):147-149. doi: 10.1080/08897077.2020.1752351.
2
The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up.多汗症的病因、诊断和治疗：全面综述：病因和临床评估。
J Am Acad Dermatol. 2019 Sep;81(3):657-666. doi: 10.1016/j.jaad.2018.12.071. Epub 2019 Jan 31.
3
Hyperhidrosis: Management Options.
多汗症：治疗选择。
Am Fam Physician. 2018 Jun 1;97(11):729-734.
4
Oxybutynin as an alternative treatment for hyperhidrosis.奥昔布宁作为多汗症的替代治疗方法。
An Bras Dermatol. 2017 Mar-Apr;92(2):217-220. doi: 10.1590/abd1806-4841.201755126.
5
Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment.格隆溴铵诱发的颅面部代偿性多汗症用奥昔布宁成功治疗：一种新的不良反应及后续成功治疗的报告
Dermatol Online J. 2016 Oct 15;22(10):13030/qt4wp1g44b.
6
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?阿片类物质使用障碍的初级保健管理：禁欲、美沙酮还是丁丙诺啡-纳洛酮？
Can Fam Physician. 2017 Mar;63(3):200-205.
7
Methadone-Induced Hyperhidrosis Treated With Oxybutynin.用奥昔布宁治疗美沙酮引起的多汗症。
J Addict Med. 2017 May/Jun;11(3):237-238. doi: 10.1097/ADM.0000000000000300.
8
Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians.
J Subst Abuse Treat. 2017 Mar;74:7-15. doi: 10.1016/j.jsat.2016.12.002. Epub 2016 Dec 14.
9
Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.药物性多汗症和少汗症：发病率、预防及管理
Drug Saf. 2008;31(2):109-26. doi: 10.2165/00002018-200831020-00002.